BR112013011949A2 - "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis" - Google Patents
"indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis"Info
- Publication number
- BR112013011949A2 BR112013011949A2 BR112013011949A BR112013011949A BR112013011949A2 BR 112013011949 A2 BR112013011949 A2 BR 112013011949A2 BR 112013011949 A BR112013011949 A BR 112013011949A BR 112013011949 A BR112013011949 A BR 112013011949A BR 112013011949 A2 BR112013011949 A2 BR 112013011949A2
- Authority
- BR
- Brazil
- Prior art keywords
- indoles
- preparing
- processes
- pharmaceutical compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10195468.3 | 2010-12-16 | ||
EP10195468 | 2010-12-16 | ||
PCT/EP2011/073011 WO2012080447A1 (en) | 2010-12-16 | 2011-12-16 | Indoles as respiratory syncytial virus antiviral agents |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013011949A2 true BR112013011949A2 (pt) | 2016-08-23 |
BR112013011949B1 BR112013011949B1 (pt) | 2021-11-23 |
Family
ID=43875270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013011949-7A BR112013011949B1 (pt) | 2010-12-16 | 2011-12-16 | Indóis, seu uso como agentes antivirais do vírus sincicial respiratório, composição farmacêutica que os compreende e processos para preparar os mesmos |
Country Status (31)
Country | Link |
---|---|
US (3) | US8921560B2 (pt) |
EP (1) | EP2651922B1 (pt) |
JP (2) | JP5945278B2 (pt) |
KR (1) | KR101914606B1 (pt) |
CN (1) | CN103347875B (pt) |
AR (1) | AR084335A1 (pt) |
AU (1) | AU2011343256C1 (pt) |
BR (1) | BR112013011949B1 (pt) |
CA (1) | CA2822000C (pt) |
CL (1) | CL2013001715A1 (pt) |
CY (1) | CY1117763T1 (pt) |
DK (1) | DK2651922T3 (pt) |
EA (1) | EA022339B1 (pt) |
ES (1) | ES2572258T3 (pt) |
HK (1) | HK1185613A1 (pt) |
HR (1) | HRP20160533T1 (pt) |
HU (1) | HUE028009T2 (pt) |
IL (1) | IL225641A (pt) |
ME (1) | ME02406B (pt) |
MX (1) | MX339944B (pt) |
MY (1) | MY163981A (pt) |
NZ (1) | NZ609487A (pt) |
PL (1) | PL2651922T3 (pt) |
RS (1) | RS54746B1 (pt) |
SG (1) | SG189866A1 (pt) |
SI (1) | SI2651922T1 (pt) |
SM (1) | SMT201600142B (pt) |
TW (1) | TWI515187B (pt) |
UA (1) | UA109792C2 (pt) |
WO (1) | WO2012080447A1 (pt) |
ZA (1) | ZA201304423B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
TWI530495B (zh) | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
TWI501967B (zh) * | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
WO2013186333A1 (en) * | 2012-06-15 | 2013-12-19 | Janssen R&D Ireland | 1,3 -dihydro- 2h-benzimidazol- 2 -one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents |
CN104540816A (zh) * | 2012-06-15 | 2015-04-22 | 爱尔兰詹森研发公司 | 作为呼吸道合胞病毒抗病毒剂的被杂环取代的1,3-二氢-2h-苯并咪唑-2-酮衍生物 |
ES2600318T3 (es) * | 2012-07-10 | 2017-02-08 | F. Hoffmann-La Roche Ag | Nuevos indazoles para el tratamiento y profilaxis de infección por virus sincitial respiratorio |
SG11201503025WA (en) | 2012-10-16 | 2015-06-29 | Janssen Sciences Ireland Uc | Rsv antiviral compounds |
CN114716426A (zh) | 2013-08-21 | 2022-07-08 | 詹森生物制药有限公司 | 抗病毒化合物 |
TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為rsv抗病毒化合物之螺脲化合物 |
SG11201700851WA (en) * | 2014-08-05 | 2017-03-30 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
EA201792028A1 (ru) | 2015-03-13 | 2018-04-30 | Форма Терапьютикс, Инк. | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 |
RU2738232C2 (ru) | 2015-07-22 | 2020-12-09 | Энанта Фармасьютикалс, Инк. | Производные бензодиазепина как ингибиторы rsv |
SG11201804098TA (en) | 2015-11-20 | 2018-06-28 | Forma Therapeutics Inc | Purinones as ubiquitin-specific protease 1 inhibitors |
CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
MY197217A (en) * | 2016-02-03 | 2023-06-01 | Janssen Sciences Ireland Uc | Combination products for the treatment of rsv |
US20200288710A1 (en) | 2016-03-15 | 2020-09-17 | Bayer Cropscience Aktiengesellschaft | Substituted sulphonamides for controlling animal pests |
TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
CN111386118B (zh) | 2017-09-29 | 2023-05-09 | 英安塔制药有限公司 | 作为rsv抑制剂的组合药物剂 |
MX2020004917A (es) | 2017-11-13 | 2020-08-06 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona. |
TW201936193A (zh) | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 使用組合產品治療rsv |
SG11202110137VA (en) | 2019-03-18 | 2021-10-28 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
KR20220101083A (ko) | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스 헤테로사이클릭 화합물 |
US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
US20240109894A1 (en) * | 2019-10-30 | 2024-04-04 | Janssen Sciences Ireland Unlimited Company | Synthesis of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2-yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one |
BR112022008883A2 (pt) | 2019-11-07 | 2022-08-23 | Bayer Ag | Sulfonil amidas substituídas para controle de pragas animais |
UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
WO2021250180A1 (en) | 2020-06-11 | 2021-12-16 | Janssen Sciences Ireland Unlimited Company | Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same |
US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
KR20230161976A (ko) | 2021-02-26 | 2023-11-28 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스성 헤테로사이클릭 화합물 |
WO2022184606A1 (en) | 2021-03-01 | 2022-09-09 | Janssen Sciences Ireland Unlimited Company | Synthesis of rilematovir |
CN114014856B (zh) * | 2021-11-26 | 2023-12-22 | 嘉兴安谛康生物科技有限公司 | 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514162A (ja) | 1996-07-08 | 2002-05-14 | デュポン ファーマシューティカルズ カンパニー | Xa因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体 |
WO2000020400A1 (en) | 1998-10-05 | 2000-04-13 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
CN1344256A (zh) | 1998-12-18 | 2002-04-10 | Axys药物公司 | (杂)芳基双环杂芳基衍生物,其制备方法和用作蛋白酶抑制剂的用途 |
EP1196409B1 (en) | 1999-06-28 | 2004-02-04 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
PL198021B1 (pl) | 1999-06-28 | 2008-05-30 | Janssen Pharmaceutica Nv | Pochodna benzoimidazolu lub imidazopirydyny, jej zastosowanie i sposób otrzymywania oraz kompozycja farmaceutyczna |
US6534535B1 (en) * | 1999-08-12 | 2003-03-18 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
EP1263754A1 (en) * | 2000-02-01 | 2002-12-11 | Millennium Pharmaceuticals, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
EP1255750A1 (en) * | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
US6489338B2 (en) * | 2000-06-13 | 2002-12-03 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrimidine antiviral agents |
US6506738B1 (en) * | 2000-09-27 | 2003-01-14 | Bristol-Myers Squibb Company | Benzimidazolone antiviral agents |
PL369432A1 (en) | 2001-12-10 | 2005-04-18 | Bristol-Myers Squibb Company | Bis hydrochloride monohydrate salt of rsv fusion inhibitor |
US6919331B2 (en) * | 2001-12-10 | 2005-07-19 | Bristol-Myers Squibb Company | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents |
WO2003056344A2 (en) | 2001-12-21 | 2003-07-10 | Sense Proteomic Limited | Protein analysis using mass spectrometry |
WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
AR043692A1 (es) | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
US7343930B2 (en) | 2004-12-03 | 2008-03-18 | Masco Corporation Of Indiana | Sprayer with non-faucet control |
MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
EP2152674B1 (en) | 2007-05-22 | 2011-08-03 | Boehringer Ingelheim International GmbH | Benzimidazolone chymase inhibitors |
FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
TWI530495B (zh) * | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
TWI501967B (zh) * | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
TWI541241B (zh) * | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
EP2652652B1 (en) | 2010-12-17 | 2019-11-20 | Sanofi-Aventis Deutschland GmbH | Medicament administration |
CN104540816A (zh) | 2012-06-15 | 2015-04-22 | 爱尔兰詹森研发公司 | 作为呼吸道合胞病毒抗病毒剂的被杂环取代的1,3-二氢-2h-苯并咪唑-2-酮衍生物 |
WO2013186333A1 (en) | 2012-06-15 | 2013-12-19 | Janssen R&D Ireland | 1,3 -dihydro- 2h-benzimidazol- 2 -one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents |
JP2015523350A (ja) | 2012-06-15 | 2015-08-13 | ヤンセン・アールアンドデイ・アイルランド | Rsウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規1,3−ジヒドロ−2h−ベンゾイミダゾル−2−オン誘導体 |
EA201590023A1 (ru) | 2012-06-15 | 2015-05-29 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса |
SG11201503025WA (en) | 2012-10-16 | 2015-06-29 | Janssen Sciences Ireland Uc | Rsv antiviral compounds |
-
2011
- 2011-12-15 TW TW100146391A patent/TWI515187B/zh active
- 2011-12-16 ES ES11794793T patent/ES2572258T3/es active Active
- 2011-12-16 NZ NZ609487A patent/NZ609487A/en unknown
- 2011-12-16 UA UAA201304193A patent/UA109792C2/ru unknown
- 2011-12-16 ME MEP-2016-97A patent/ME02406B/me unknown
- 2011-12-16 EA EA201390883A patent/EA022339B1/ru unknown
- 2011-12-16 SI SI201130824A patent/SI2651922T1/sl unknown
- 2011-12-16 BR BR112013011949-7A patent/BR112013011949B1/pt active IP Right Grant
- 2011-12-16 SG SG2013026729A patent/SG189866A1/en unknown
- 2011-12-16 JP JP2013543801A patent/JP5945278B2/ja active Active
- 2011-12-16 AR ARP110104740A patent/AR084335A1/es active IP Right Grant
- 2011-12-16 KR KR1020137016980A patent/KR101914606B1/ko active IP Right Grant
- 2011-12-16 RS RS20160332A patent/RS54746B1/sr unknown
- 2011-12-16 CN CN201180060358.8A patent/CN103347875B/zh active Active
- 2011-12-16 EP EP11794793.7A patent/EP2651922B1/en active Active
- 2011-12-16 CA CA2822000A patent/CA2822000C/en active Active
- 2011-12-16 WO PCT/EP2011/073011 patent/WO2012080447A1/en active Application Filing
- 2011-12-16 MY MYPI2013001279A patent/MY163981A/en unknown
- 2011-12-16 DK DK11794793.7T patent/DK2651922T3/en active
- 2011-12-16 HU HUE11794793A patent/HUE028009T2/en unknown
- 2011-12-16 AU AU2011343256A patent/AU2011343256C1/en active Active
- 2011-12-16 PL PL11794793.7T patent/PL2651922T3/pl unknown
- 2011-12-16 MX MX2013006887A patent/MX339944B/es active IP Right Grant
- 2011-12-16 US US13/993,200 patent/US8921560B2/en active Active
-
2013
- 2013-04-09 IL IL225641A patent/IL225641A/en active IP Right Grant
- 2013-06-13 CL CL2013001715A patent/CL2013001715A1/es unknown
- 2013-06-14 ZA ZA2013/04423A patent/ZA201304423B/en unknown
- 2013-11-21 HK HK13113019.5A patent/HK1185613A1/zh unknown
-
2014
- 2014-11-18 US US14/546,289 patent/US9321768B2/en active Active
-
2016
- 2016-03-11 JP JP2016048038A patent/JP2016145236A/ja active Pending
- 2016-04-22 US US15/136,769 patent/US9944638B2/en active Active
- 2016-05-19 HR HRP20160533TT patent/HRP20160533T1/hr unknown
- 2016-05-20 SM SM201600142T patent/SMT201600142B/it unknown
- 2016-05-24 CY CY20161100449T patent/CY1117763T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013011949A2 (pt) | "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis" | |
BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
BRPI1009481A2 (pt) | compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos | |
BRPI0918502A2 (pt) | aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos | |
BR112013013668A2 (pt) | moduladores 7-deazapurina de histona metiltransferase, e métodos de uso dos mesmos | |
BRPI1105247A2 (pt) | "estrutura de embalagem para recipientes para uso farmacêutico" | |
BRPI0913726A2 (pt) | rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos | |
BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
BR112013023681A2 (pt) | compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos | |
IL224288A (en) | Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use | |
BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
CL2007002377A1 (es) | Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno. | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
BRPI0907453A2 (pt) | Compostos, uso e preparação dos mesmos | |
BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
CO6920294A2 (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
CR10665A (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
BRPI0820985A2 (pt) | Composto derivado de 5-aminociclometil-oxazondin-2-ona, medicamento e composição farmacêutica que os contém e uso dos mesmos | |
CL2014003525A1 (es) | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. | |
BRPI0915527A2 (pt) | pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos | |
BR112014009822A2 (pt) | composições farmacêuticas compreendendo dgla e/ou 15-hetre e métodos de uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001 |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |